FREZENT Biological Solutions

FREZENT Biological Solutions is a preclinical-stage oncology therapeutics company based in New York. The company is focused on developing bispecific antibodies and antibody-drug conjugates to target dormant cancer cells that may cause cancer recurrence. These dormant cancer cells are residual portions of a tumor not completely eliminated by treatment, remaining undetectable in the body before potentially transforming into fast-growing tumors.

FREZENT's approach involves developing therapeutics to neutralize the metabolic factors supplied by the tumor microenvironment, which support dormant cancer cells. By blocking these factors, the company aims to starve the cancer cells and induce cell death, thus preventing the reactivation of dormant cancer cells. The company's mission is to secure a future where long-lasting remission becomes a reality for all cancer patients.

The latest milestone for FREZENT was a Seed Round investment on 26 September 2023. The investors in this round were SOSV and indiebio. With its innovative approach to targeting dormant cancer cells, FREZENT aims to revolutionize the prognosis for patients with advanced stage cancer.